Acción DISCOVERY LABORATORIES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Discovery Laboratories, Inc. Nasdaq

Acciones

US2546684034

Precio de cierre Nasdaq
Otros sitios de cotización
- USD - Gráfico intradía de Discovery Laboratories, Inc.
16/04 Windtree Therapeutics, Inc. informa de los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI
10/04 Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Windtree Therapeutics Regains Compliance with Nasdaq
Windtree Therapeutics : April'24 Corporate Presentation
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción WINT
  4. Acción
  5. Noticias Discovery Laboratories, Inc.
  6. Otros idiomas